Primary treatment patterns and survival of cervical cancer in Sweden: A population-based Swedish Gynecologic Cancer Group Study

Research output: Contribution to journalArticle

Standard

Primary treatment patterns and survival of cervical cancer in Sweden : A population-based Swedish Gynecologic Cancer Group Study. / Bjurberg, Maria; Holmberg, Erik; Borgfeldt, Christer; Flöter-Rådestad, Angelique; Dahm-Kähler, Pernilla; Hjerpe, Elisabet; Högberg, Thomas; Kjølhede, Preben; Marcickiewicz, Janusz; Rosenberg, Per; Stålberg, Karin; Tholander, Bengt; Hellman, Kristina; Åvall-Lundqvist, Elisabeth.

In: Gynecologic Oncology, Vol. 155, No. 2, 11.2019, p. 229-236.

Research output: Contribution to journalArticle

Harvard

Bjurberg, M, Holmberg, E, Borgfeldt, C, Flöter-Rådestad, A, Dahm-Kähler, P, Hjerpe, E, Högberg, T, Kjølhede, P, Marcickiewicz, J, Rosenberg, P, Stålberg, K, Tholander, B, Hellman, K & Åvall-Lundqvist, E 2019, 'Primary treatment patterns and survival of cervical cancer in Sweden: A population-based Swedish Gynecologic Cancer Group Study', Gynecologic Oncology, vol. 155, no. 2, pp. 229-236. https://doi.org/10.1016/j.ygyno.2019.08.022

APA

CBE

Bjurberg M, Holmberg E, Borgfeldt C, Flöter-Rådestad A, Dahm-Kähler P, Hjerpe E, Högberg T, Kjølhede P, Marcickiewicz J, Rosenberg P, Stålberg K, Tholander B, Hellman K, Åvall-Lundqvist E. 2019. Primary treatment patterns and survival of cervical cancer in Sweden: A population-based Swedish Gynecologic Cancer Group Study. Gynecologic Oncology. 155(2):229-236. https://doi.org/10.1016/j.ygyno.2019.08.022

MLA

Vancouver

Author

Bjurberg, Maria ; Holmberg, Erik ; Borgfeldt, Christer ; Flöter-Rådestad, Angelique ; Dahm-Kähler, Pernilla ; Hjerpe, Elisabet ; Högberg, Thomas ; Kjølhede, Preben ; Marcickiewicz, Janusz ; Rosenberg, Per ; Stålberg, Karin ; Tholander, Bengt ; Hellman, Kristina ; Åvall-Lundqvist, Elisabeth. / Primary treatment patterns and survival of cervical cancer in Sweden : A population-based Swedish Gynecologic Cancer Group Study. In: Gynecologic Oncology. 2019 ; Vol. 155, No. 2. pp. 229-236.

RIS

TY - JOUR

T1 - Primary treatment patterns and survival of cervical cancer in Sweden

T2 - A population-based Swedish Gynecologic Cancer Group Study

AU - Bjurberg, Maria

AU - Holmberg, Erik

AU - Borgfeldt, Christer

AU - Flöter-Rådestad, Angelique

AU - Dahm-Kähler, Pernilla

AU - Hjerpe, Elisabet

AU - Högberg, Thomas

AU - Kjølhede, Preben

AU - Marcickiewicz, Janusz

AU - Rosenberg, Per

AU - Stålberg, Karin

AU - Tholander, Bengt

AU - Hellman, Kristina

AU - Åvall-Lundqvist, Elisabeth

PY - 2019/11

Y1 - 2019/11

N2 - Objective: Survival in cervical cancer has improved little over the last decades. We aimed to elucidate primary treatment patterns and survival. Methods: Population-based study of patients included in the Swedish Quality Registry for Gynecologic Cancer diagnosed 2011–2015. Main outcome was 5-year relative survival (RS). Age-standardised RS (AS-RS) was estimated for the total cohort and for the pooled study population of squamous, adenosquamous-, adenocarcinoma. Results: Median follow-up time was 4.6 years. The study population consisted of 2141 patients; 97% of the 2212 patients in the total cohort and the 5-year AS-RS was 71% and 70%, respectively. RS stage IB1: surgery alone 95% vs. 72% for definitive chemoradiotherapy (CT-RT) (p < 0.001). In stage IIA1 74% had CT-RT, and 47% of operated patients received adjuvant (CT)-RT. RS stage IB2: surgically treated 81% (69% received adjuvant (CT)-RT) vs. 76% for (CT)-RT (p = 0.73). RS stage IIB: 77% for CT-RT + brachytherapy (BT), 37% for RT + BT (p = 0.045) and 27% for RT-BT (p < 0.001). Stages III-IVA; <40% received CT-RT + BT, RS 45% vs. 18% for RT-BT (RR 4.1, p < 0.001). RS stage IVB 7%. Conclusion: Primary treatment of cervical cancer in Sweden adhered to evidence-based standard of care. Areas of improvement include optimising treatment for stages III-IVA, and avoiding combining surgery and radiotherapy.

AB - Objective: Survival in cervical cancer has improved little over the last decades. We aimed to elucidate primary treatment patterns and survival. Methods: Population-based study of patients included in the Swedish Quality Registry for Gynecologic Cancer diagnosed 2011–2015. Main outcome was 5-year relative survival (RS). Age-standardised RS (AS-RS) was estimated for the total cohort and for the pooled study population of squamous, adenosquamous-, adenocarcinoma. Results: Median follow-up time was 4.6 years. The study population consisted of 2141 patients; 97% of the 2212 patients in the total cohort and the 5-year AS-RS was 71% and 70%, respectively. RS stage IB1: surgery alone 95% vs. 72% for definitive chemoradiotherapy (CT-RT) (p < 0.001). In stage IIA1 74% had CT-RT, and 47% of operated patients received adjuvant (CT)-RT. RS stage IB2: surgically treated 81% (69% received adjuvant (CT)-RT) vs. 76% for (CT)-RT (p = 0.73). RS stage IIB: 77% for CT-RT + brachytherapy (BT), 37% for RT + BT (p = 0.045) and 27% for RT-BT (p < 0.001). Stages III-IVA; <40% received CT-RT + BT, RS 45% vs. 18% for RT-BT (RR 4.1, p < 0.001). RS stage IVB 7%. Conclusion: Primary treatment of cervical cancer in Sweden adhered to evidence-based standard of care. Areas of improvement include optimising treatment for stages III-IVA, and avoiding combining surgery and radiotherapy.

KW - Cervical cancer

KW - Radiotherapy

KW - Surgery

KW - Survival

KW - Treatment

U2 - 10.1016/j.ygyno.2019.08.022

DO - 10.1016/j.ygyno.2019.08.022

M3 - Article

VL - 155

SP - 229

EP - 236

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 1095-6859

IS - 2

ER -